Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer

Mostrar otras versiones (1)

BACKGROUND: Head and neck squamous cell carcinoma not associated with HPV (HPV-unrelated HNSCC) is associated with a high rate of recurrence and poor survival. METHODS: We conducted a clinical trial in 14 patients with newly diagnosed HPV-unrelated HNSCC to evaluate the safety and efficacy of neoadj...

Descripción completa

Detalles Bibliográficos
Autores principales: Redman, Jason M., Friedman, Jay, Robbins, Yvette, Sievers, Cem, Yang, Xinping, Lassoued, Wiem, Sinkoe, Andrew, Papanicolau-Sengos, Antonios, Lee, Chyi-Chia, Marte, Jennifer L., Turkbey, Evrim, Mydlarz, Wojtek, Joshi, Arjun, London, Nyall R., Pierce, Matthew, Taylor, Rodney, Hong, Steven, Nguyen, Andy, Soon-Shiong, Patrick, Schlom, Jeffrey, Gulley, James L., Allen, Clint T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479764/
https://www.ncbi.nlm.nih.gov/pubmed/35727629
http://dx.doi.org/10.1172/JCI161400

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479764/
https://www.ncbi.nlm.nih.gov/pubmed/35727629
http://dx.doi.org/10.1172/JCI161400

Ejemplares similares